Crescent Biopharma (CBIO) Total Liabilities (2013 - 2026)

Crescent Biopharma (CBIO) has 14 years of Total Liabilities data on file, last reported at $15.3 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $15.3 million, up 484.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.3 million (up 484.01% YoY), and the FY2025 annual result was $37.3 million, down 20.84% from the prior year.
• Total Liabilities eased to $15.3 million in Q1 2026 per CBIO's latest filing, from $37.3 million in the prior quarter.
• Over five years, Total Liabilities peaked at $47.1 million in Q4 2024 and troughed at $2.6 million in Q1 2025.
• A 5-year average of $13.1 million and a median of $7.8 million in 2022 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities soared 582.35% in 2024, then tumbled 50.57% in 2025.
• A 5-year view of Total Liabilities shows it stood at $8.9 million in 2022, then retreated by 22.28% to $6.9 million in 2023, then soared by 582.35% to $47.1 million in 2024, then fell by 20.84% to $37.3 million in 2025, then sank by 59.01% to $15.3 million in 2026.
• Business Quant data shows CBIO's Total Liabilities at $15.3 million in Q1 2026, $37.3 million in Q4 2025, and $21.6 million in Q3 2025.